Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics
Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B.
Share
The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals.
Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, accepted the award on behalf of Novotech at the Citeline Awards ceremony held on May 8, 2025, in Boston. Katie Tarashuck, Vice President of Finance at Tune Therapeutics, attended as a partner representative.
Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and therapeutic expertise with Tune's innovative scientific platform and agile development strategy.
'This recognition from Citeline reflects not only the strength of our partnership with Tune Therapeutics but also the dedication of our global teams to help bring novel therapies to patients faster,' said Dr. John Moller, CEO of Novotech. 'We are honored to collaborate with visionary biotech companies like Tune and look forward to continuing to deliver clinical excellence across the development spectrum.'
'Tune is delighted to receive this partnership award with Novotech," said Dr. Heidi Zhang, Chief Development Officer at Tune Therapeutics. "Together, we have achieved a global first in bringing this epigenome editing therapy to the clinic, and new hope to over 250 million people living with CHB worldwide.'
The award acknowledges Novotech's ability to align closely with biotech partners, applying its regulatory and therapeutic expertise to support the effective delivery of clinical trials across varied global settings.
'The strength of this collaboration,' added Dr. Zhang, 'lies in our shared commitment to transparency, willingness to confront challenges directly, and ability to act quickly and effectively as one team.'
About Novotech
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results.
For more information or to speak to an expert team member visit www.Novotech-CRO.com.
epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA. Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common and chronic diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 days ago
- Business Wire
Novotech Awarded Veeva Hero Award at 2025 Veeva R&D and Quality Summit
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea. Novotech, a globally recognized full-service clinical research organization (CRO), is proud to announce that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea. Share Each year, Veeva recognizes industry-leading companies and organizations driving transformational change and growth as "Veeva Heroes." This year, Novotech was recognized for its early and proactive adoption of Veeva platforms to streamline global clinical trials through strong collaboration across sponsors, CRO, and trial sites accelerating drug development and reinforcing its evolution from a regional leader to a global player. 'This recognition was made possible thanks to the dedication and hard work of our cross-functional internal Veeva team, whose efforts were instrumental in achieving this milestone,' stated Dr. Yooni Kim, Managing Director, Asia-Pacific. 'Their commitment and collaborative spirit exemplify the core values that drive our success.' The strategic collaboration between has significantly contributed to mutual growth in the Korean market, enabling biotech and pharma sponsors to accelerate product development and expedite the delivery of innovative therapies to patients. Novotech remains committed to advancing this partnership fostering innovation and driving excellence in clinical research. For further information, please visit About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
Forbes
5 days ago
- Forbes
Beyond Diagnosis: Understanding The Lived Experience And Unmet Needs In Chronic Hepatitis B
Chronic hepatitis B (CHB) affects more than 254 million people globally, with 1.2 million new infections occurring each year.1 And while it has the potential to cause severe long-term liver problems for those affected, many impacts of this often-misunderstood global health issue remain unseen. The Human Impact of Chronic Hepatitis B CHB has a high potential to cause cancer, and those living with hepatitis B may face a similar or even greater risk of developing a malignancy than individuals who smoke a pack of 20 cigarettes daily.2 Liver cancer is the third most common cause of cancer mortality3 and CHB is the largest cause of hepatocellular carcinoma (a type of liver cancer) or HCC.4 To better address the unmet needs of those living with CHB, it is important to understand the realities of the human experience beyond the medical diagnosis and to fully appreciate the personal challenges they face. Receiving a CHB diagnosis can be an emotionally and psychologically challenging experience. 'Patients often face an initial wave of surprise and disbelief, which quickly gives way to concerns about what the future holds. The long-term health implications can be worrying, often causing significant mental health issues,' said Laura Malone, Director of Partnerships and Resources, World Hepatitis Alliance. Living with Misconceptions and Stigma Much of this psychological impact can be attributed to the misconceptions surrounding living with CHB. CHB is often confused with other liver infections. But while viral infections like hepatitis C have had important treatment breakthroughs in the last 10-15 years,5 hepatitis B has not. As a result, hepatitis B infection is now considerably more common globally than hepatitis C, especially in low- and middle-income countries.1 A diagnosis of CHB can lead individuals to experience isolation and loneliness as they worry about the impact of their diagnosis on relationships and the risk of discrimination. They can often grapple with fear and anxiety about their health and the potential progression of their disease despite treatment. 6 They can also feel stigmatized, leading to social withdrawal as individuals seek to avoid judgment from wider society.6 CHB is mostly acquired in childhood with the HBV virus often transmitted during childbirth from mother to child when the infant's immature immune system cannot defend against the virus.7 Yet misconceptions, such as the belief that CHB results from poor lifestyle choices, can fuel unjust judgment and unwarranted concerns that it can be spread by normal day to day contact such as sharing cutlery. To challenge these misconceptions, organizations like the World Hepatitis Alliance are campaigning actively to correct the myths and misunderstandings associated with viral infections like CHB. Laura Malone, Director of Partnerships and Resources, World Hepatitis Alliance said, 'There is an urgent need to challenge the misperceptions around CHB so that stigma does not get in the way of people getting the help they need. The benefits of future innovations will never be felt if those who are living with CHB avoid coming forward for medical care because they are afraid of having a negative experience in a healthcare setting." What Functional Cure Would Mean for Those with CHB Most people living with CHB may require lifelong treatment with daily medication to reduce their risk of long-term health problems. A functional cure is when levels of virus in the blood and liver are so low that the infection is controlled without medication – current standard of care treatments achieve this in only 1-8% patients. 8,9,10 Functional cure can lower the risk of serious liver problems like cirrhosis and cancer. It also means people no longer test positive for hepatitis B, which can help reduce stigma and improve their mental well-being. 9 A functional cure can indicate that the individual's immune system is effectively managing the infection, eliminating the need for ongoing medication.9 Joyeta Das, Global Medical Affairs Lead CHB at GSK, emphasizes how a functional cure provides not only physical protection against severe outcomes but also profound psychological relief: 'A functional cure offers optimism and freedom, helping alleviate the psychological impact associated with CHB. Further scientific research into new ways to offer those who are infected the potential for an effective and durable functional cure is urgently needed.' While we wait for these advances, increased testing and diagnosis will help to reduce the health economic costs of untreated infection and help patients reduce their risks of serious and costly liver complications. New scientific research is accelerating the journey to a future where CHB no longer creates such a high burden on individuals and society, meanwhile health systems must prepare so that those innovations can be accessed by those who most need them.
Business Upturn
17-07-2025
- Business Upturn
Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Economics
Business Wire India With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical Contract Research Organization (CRO) and scientific advisory company, offers insight into this next frontier of immunotherapy. In-Vivo CAR Therapies – Global Research and Development Landscape (2025) report explores the accelerating innovation in in-vivo CAR-T (Chimeric Antigen Receptor) technologies and their potential to reshape treatment across oncology, autoimmune diseases, and other complex indications. This press release features multimedia. View the full release here: In Vivo Car T Infographic from Novotech Traditional ex-vivo CAR-T therapies require extracting a patient's T cells, engineering them in specialized labs, and reinfusing them, a process that is time-intensive, expensive, and logistically complex. These barriers have significantly restricted patient access. In contrast, in-vivo CAR-T therapies aim to overcome these challenges by engineering T cells directly within the patient's body using delivery technologies such as viral vectors, lipid nanoparticles (LNPs), and advanced mRNA platforms. The result: faster, more scalable, and potentially off-the-shelf treatments that can expand access, reduce costs, and streamline the patient experience. In-vivo CAR-T platforms are now being explored not only for hematologic malignancies, but also for solid tumors and autoimmune diseases—areas where traditional CAR-T approaches have faced limitations. Emerging delivery innovations and new combination strategies are driving this expansion. As a result, in-vivo CAR-T therapies are positioned to reshape clinical practice, expanding their applicability across oncology, autoimmune diseases, and beyond. The report provides key insights for sponsors, investors, and researchers into one of the most transformative areas of next-generation cell therapy. It includes: The technological evolution of CAR platforms and delivery systems. The expanding global pipeline of in-vivo CAR assets and clinical programs. Innovations in lipid nanoparticle (LNP) and viral vector delivery strategies. Commercial and regulatory considerations shaping future adoption. Opportunities for in-vivo CAR approaches beyond oncology, including autoimmune diseases and fibrosis. Novotech has an established track record of supporting in-vivo CAR-T programs globally, including conducting the world's first in-vivo CAR clinical trial, highlighting its leadership and deep expertise in advanced therapeutics, including gene and cell therapies. The company has also conducted more than 100 ATMP studies, spanning gene therapies, gene-modified cell therapies, and mRNA products. Novotech is also actively partnering with biotech sponsors advancing in-vivo CAR pipelines. Download the full whitepaper to explore the key trends and opportunities driving the future of in-vivo CAR-T therapy. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
